Literature DB >> 2153905

Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.

P De Isabella1, G Capranico, M Binaschi, S Tinelli, F Zunino.   

Abstract

A multidrug-resistant variant of the P388 leukemia cell line exhibits multiple biochemical changes, including reduced drug accumulation and markedly reduced DNA strand breakage induced by anthracyclines. To investigate whether the reduced formation of drug-induced DNA breaks was due to alteration of DNA topoisomerase II activity, nuclear extracts and partially purified enzymes from the sensitive line and the resistant subline were compared. DNA topoisomerase II activity in 0.35 M NaCl nuclear extracts from sensitive cells was approximately 1.7 times higher than that found in extracts from resistant cells, as determined by ability to unknot P4 phage DNA. In addition, it was found that teniposide-stimulated topoisomerase II DNA cleavage activity of nuclear extract from resistant cells was at least 10-fold lower than that from sensitive cells. This differential sensitivity paralleled a similar drug response of nuclei, as determined by the alkaline elution method. However, partially purified DNA topoisomerase II showed similar drug sensitivity in both cell lines. This finding suggests the presence of a modulating factor, which may be lost during purification. These results, indicating a reduction of both catalytic activity and DNA cleavage activity of DNA topoisomerase II in P388 multidrug-resistant cells, emphasize the importance of DNa topoisomerase function in the resistance mechanism. Thus, the concomitant involvement of multiple mechanisms could explain the high degree of resistance of these cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153905

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage.

Authors:  M Bigioni; F Zunino; G Capranico
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

2.  In vitro cytotoxicity of S16020-2, a new olivacine derivative.

Authors:  S Léonce; V Perez; M R Casabianca-Pignede; M Anstett; E Bisagni; A Pierré; G Atassi
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Topoisomerase II in multiple drug resistance.

Authors:  G A Hofmann; M R Mattern
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative.

Authors:  A Pierré; T A Dunn; L Kraus-Berthier; S Léonce; D Saint-Dizier; G Régnier; A Dhainaut; M Berlion; J P Bizzari; G Atassi
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

5.  In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176.

Authors:  Manabu Takagi; Takuya Honmura; Shuuji Watanabe; Reiko Yamaguchi; Masaki Nogawa; Ikumi Nishimura; Fumitaka Katoh; Masato Matsuda; Hiroyoshi Hidaka
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

6.  Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.

Authors:  P De Isabella; F Zunino; G Capranico
Journal:  Nucleic Acids Res       Date:  1995-01-25       Impact factor: 16.971

7.  DNA-Binding and Topoisomerase-I-Suppressing Activities of Novel Vanadium Compound Van-7.

Authors:  Xiao-Mei Mo; Zhan-Fang Chen; Xin Qi; Yan-Tuan Li; Jing Li
Journal:  Bioinorg Chem Appl       Date:  2012-09-30       Impact factor: 7.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.